Parabilis Medicines (PBLS) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Initiated Coverage | Outperform | $40.00 | Jul 6, 2026 |
| Guggenheim | Initiated Coverage | Buy | $40.00 | Jul 6, 2026 |
| B of A Securities | Initiated Coverage | Buy | $45.00 | Jul 6, 2026 |
Frequently asked questions
What is the price target for PBLS stock?
The average 12-month analyst price target for Parabilis Medicines (PBLS) is $41.67, with a high estimate of $45.00 and a low of $40.00, across 3 analysts.
Is PBLS a buy, sell, or hold?
Analysts covering Parabilis Medicines currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PBLS?
The average price target of $41.67 implies 7.87% upside from the last price of $38.63.
What is the latest analyst rating on PBLS?
On Jul 6, 2026, Leerink Partners initiated coverage of Parabilis Medicines at Outperform with a price target of $40.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.